FY2026 EPS Estimates for Scholar Rock Increased by Analyst

Scholar Rock Holding Co. (NASDAQ:SRRK) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for Scholar Rock in a report issued on Tuesday, November 26th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.57) for the year, up from their previous estimate of ($1.68). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

Several other analysts have also recently commented on SRRK. BMO Capital Markets increased their target price on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, October 14th. Truist Financial boosted their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Piper Sandler increased their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Finally, Wedbush boosted their price objective on shares of Scholar Rock from $40.00 to $47.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and a consensus price target of $40.43.

Scholar Rock Trading Up 4.6 %

SRRK stock opened at $39.90 on Thursday. The business has a fifty day moving average price of $24.88 and a 200 day moving average price of $14.70. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $43.38. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of -16.23 and a beta of 0.47.

Insider Activity

In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the sale, the insider now owns 49,285 shares in the company, valued at approximately $1,262,681.70. The trade was a 37.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Edward H. Myles sold 206,240 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $26.56, for a total value of $5,477,734.40. Following the completion of the transaction, the chief financial officer now owns 161,088 shares in the company, valued at $4,278,497.28. This represents a 56.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,823,322 shares of company stock valued at $56,411,627. 19.20% of the stock is currently owned by insiders.

Institutional Trading of Scholar Rock

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after acquiring an additional 514 shares during the last quarter. Quarry LP boosted its position in shares of Scholar Rock by 3,443.3% during the third quarter. Quarry LP now owns 4,500 shares of the company’s stock worth $36,000 after purchasing an additional 4,373 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $98,000. Hsbc Holdings PLC acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $100,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Scholar Rock in the 2nd quarter valued at $103,000. 91.08% of the stock is owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.